Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy

@article{Tuxen2001SerumTM,
  title={Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy},
  author={Malgorzata K. Tuxen and Gy{\"o}rgy S{\"o}l{\'e}tormos and Per Dombernowsky},
  journal={British Journal of Cancer},
  year={2001},
  volume={84},
  pages={1301 - 1307}
}
The value of the serum tumour marker CA 125 to date has been in the monitoring of ovarian cancer patients for response to therapy and for recurrence of disease. However, despite the availability of serial data on CA 125, the problem of interpreting a change over time is still unsolved. The aim of this study was to assess the ability of CA 125 to monitor patients with ovarian cancer during postoperative chemotherapy. 255 patients with stage IC-IV ovarian cancer were allocated to the tumour… CONTINUE READING
26 Citations
40 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

125 and placental alkaline phosphatase as serum tumor markers in epithe ovarian carcinoma

  • IB Vergote, VM Abeler, OP Bormer, T Stigbrand, C Trope, K Nustad
  • Tumor Biol
  • 1992
Highly Influential
2 Excerpts

CA 125response assessm epithelial ovarian cancer

  • P Fioretti, A Gadducci, M Ferdeghini, T Bartolini, R Bianchi, V Facchini
  • Int J Cancer
  • 1992
Highly Influential
1 Excerpt

Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients

  • HB Krebs, DR Goplerud, SJ Kilpatrick, MB Myers, A Hunt
  • Am J Clin Oncol
  • 1986
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…